Regulated cell death (RCD), also well-known as programmed cell death (PCD), refers to the
form of cell death that can be regulated by a variety of biomacromolecules, which is …

Adenocarcinoma has become the most prevalent lung cancer sub-type and its frequency is
increasing. The earliest stages in the development of lung adenocarcinomas are visible …

Introduction Camrelizumab, a humanized immunoglobulin G4-κ monoclonal antibody
against programmed cell death protein 1, has exhibited antitumor activity and tolerability …

Background Standard first-line therapy for metastatic, squamous non–small-cell lung cancer
(NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed …

Lung cancer is the world's leading cause of cancer death and shows strong ancestry
disparities. By sequencing and assembling a large genomic and transcriptomic dataset of …

Introduction Data on immuno-oncology agents in Chinese patients are limited despite a
need for new therapies. We evaluated the efficacy and safety of nivolumab in a …

Background: We tested a new, investigational robotic-assisted bronchoscope system with a
remotely controlled catheter to access small peripheral bronchi with real-time driving under …

Since the discovery in 2012 of rearranged during transfection proto-oncogene gene (RET)
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …

Several epidemiological and experimental studies have demonstrated that many human
diseases are not only caused by specific genetic and environmental factors but also by gene …

Lung cancer is often diagnosed at an advanced stage and has a poor prognosis.
Conventional treatments are not effective for metastatic lung cancer therapy. Although some …